Mobidiag Symposium on Innovative Molecular Diagnostics to Be Held in Paris, France
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, will host a symposium at the 38th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI), in Paris this month. The symposium is on December 17 th from 12h45 to 13h45, in spoken French. RICAI is an annual meeting bringing together leading French clinicians and microbiologists (parasitologists, virologists, bacteriologists) and innovative commercial companies in diagnostics.
The symposium, Mobidiag’s second at a RICAI annual meeting, will showcase the Company’s automated molecular diagnostics solutions, Amplidiag® and Novodiag® , and their state-of-the-art capabilities in the rapid identification of infectious diseases and antimicrobial drug resistance. At the event, a number of leading clinicians will present data and share their experience of using Mobidiag’s technology.
Confirmed speakers at the Mobidiag symposium include:
- Mrs. Safia Nadji , Resident in Medical Biology, CHRU Lille
- Pr. Christophe Burucoa , Head of Bacteriology Hygiene Laboratory, CHU Poitiers
- Pr. Raymond Ruimy , Head of Bacteriology Laboratory, CHU Nice
- Dr. Jean-Winoc Decousser , MCU – PH, Bacteriology Laboratory – Hygiene, Hôpital Henri Mondor, Créteil
- Dr. Thomas Gueudet , Medical Biologist, Laboratoire Schuh BIO67, Strasbourg
Following the presentations, a demonstration of both Amplidiag® and Novodiag® will be made at booth No. 13, showcasing how Mobidiag can support the everyday work of healthcare practitioners.
For more details and registration visit our website . A white paper will be made available following the event.
Yann Marcy, President at Mobidiag France, commented , “At Mobidiag we are focused on developing innovative diagnostic solutions that have a real impact, and particularly on antimicrobial resistance, one of the most significant challenges in global health. Following on from the success of last year’s symposium at the RICAI conference, we look forward to hearing from key customers who will present new data and share their experiences on how Amplidiag® and Novodiag® have performed in the laboratory setting in the last 12 months.”
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
Consilium Strategic Communications
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
AL-JANADRIA-FESTIVAL17.12.2018 16:53 | Pressemeddelelse
Prince Khalid bin Abdul Aziz bin Ayyaf Announces Launch of the 33rd Edition of Al Janadria Festival Next Thursday
GA-BRIGHTREE17.12.2018 15:07 | Pressemeddelelse
Brightree Acquires Mobile Delivery Provider Apacheta to Streamline HME Delivery
CA-TRANSPHORM-INC17.12.2018 15:02 | Pressemeddelelse
Transphorm’s High Voltage GaN FETs Amp Up Marotta Controls’ Military Grade High Frequency Power Supply
NJ-CELGENE17.12.2018 13:32 | Pressemeddelelse
Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients
MARJAN17.12.2018 12:17 | Pressemeddelelse
Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid
MOBIDIAG-LTD.17.12.2018 11:15 | Pressemeddelelse
Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum